In Vitro Antimicrobial Activity of Ceftobiprole and Comparator Agents Against Streptococcus pneumoniae Responsible
Helio S Sader1, Mariana Castanheira1, Mark E Jones2
1Element Iowa City (JMI Laboratories), North Liberty, IA 52317, USA.
Abstract:
Background: Ceftobiprole is an advanced-generation cephalosporin approved in Europe in 2013 for various indications, and in the United States (US) in 2024 for community-acquired bacterial pneumonia (CABP), acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia, including right-sided endocarditis. Methods: The in vitro activity of ceftobiprole and comparators was evaluated against 2793 Streptococcus pneumoniae causing lower respiratory tract infections in 32 US sites (2016-2020), including against subsets from various geographic regions, resistance phenotypes and prevalent serotypes. Results: Ceftobiprole inhibited 99.5% of all S. pneumoniae at the MIC of ≤0.5 mg/L (MIC50/90, 0.015/0.25 mg/L). Susceptibilities of 98.2% to 100% were observed for ceftobiprole against isolates originating from each surveyed year or each US Census Division. Ceftobiprole retained activity against isolates resistant to macrolides (98.8%), tetracycline (98.2%), oral penicillin (95.4%), against multidrug-resistant isolates (97.0%), and various serotypes (93.8-100%). Ceftriaxone (97.4%) and amoxicillin-clavulanate (95.1%) also showed elevated susceptibilities overall, but inconsistent results and lower than those observed for ceftobiprole were noted against isolates with elevated penicillin MIC or specific serotypes (i.e., 19A). Conclusions: These in vitro results, coupled with documented clinical efficacy, indicate that ceftobiprole is a valuable option to treat CABP caused by S. pneumoniae in the US.
Insights
Ceftobiprole demonstrates high in vitro activity against Streptococcus pneumoniae, including resistant strains. This advanced cephalosporin is a promising treatment option for community-acquired bacterial pneumonia in the US.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Background:
- Ceftobiprole is an advanced-generation cephalosporin approved in the US in 2024.
- Indications include community-acquired bacterial pneumonia (CABP) and Staphylococcus aureus bacteremia.
Purpose of the Study:
- To evaluate the in vitro activity of ceftobiprole against Streptococcus pneumoniae.
- To assess ceftobiprole's efficacy against resistant isolates and specific serotypes.
Main Methods:
- In vitro testing of ceftobiprole and comparators.
- Evaluated 2793 S. pneumoniae isolates from 32 US sites (2016-2020).
- Analysis included geographic regions, resistance phenotypes, and serotypes.
Main Results:
- Ceftobiprole inhibited 99.5% of S. pneumoniae isolates at ≤0.5 mg/L.
- High susceptibility (98.2%-100%) observed across years, regions, and against resistant strains.
- Maintained activity against macrolide, tetracycline, and multidrug-resistant isolates.
Conclusions:
- Ceftobiprole exhibits potent in vitro activity against S. pneumoniae.
- Demonstrates consistent efficacy against various resistance mechanisms and serotypes.
- A valuable therapeutic option for CABP caused by S. pneumoniae in the US.
More Related Videos
09:26Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
07:50Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
Published on: October 25, 2024
Related Concept Videos
01:28Antimicrobial Effectiveness
01:25Mechanism of Antibiotic Resistance in MRSA
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
01:25Clinical Significance of Antibiotic Resistance
01:14Atypical Pneumonia
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...